http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 19 May 2026 07:00:27 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) completed a public offering that raised $5 million in gross proceeds through the sale of 2,659,574 common shares and common share equivalents at $1.88 per share.</p> <p>The pharmaceutical company issued 183,577 common shares and 2,475,997 pre-funded warrants to purchasers. Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.0001 per share.</p> <p>XORTX plans to use the net proceeds for working capital and general corporate purposes, including investor relations activities. The company paid E.F. Hutton & Co. a cash commission of $200,000, representing 4% of the gross proceeds, for serving as http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html Tue, 19 May 2026 07:00:27 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) completed a public offering that raised $5 million in gross proceeds through the sale of 2,659,574 common shares and common share equivalents at $1.88 per share.</p> <p>The pharmaceutical company issued 183,577 common shares and 2,475,997 pre-funded warrants to purchasers. Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.0001 per share.</p> <p>XORTX plans to use the net proceeds for working capital and general corporate purposes, including investor relations activities. The company paid E.F. Hutton & Co. a cash commission of $200,000, representing 4% of the gross proceeds, for serving as http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html Tue, 19 May 2026 07:00:27 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) completed a public offering that raised $5 million in gross proceeds through the sale of 2,659,574 common shares and common share equivalents at $1.88 per share.</p> <p>The pharmaceutical company issued 183,577 common shares and 2,475,997 pre-funded warrants to purchasers. Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.0001 per share.</p> <p>XORTX plans to use the net proceeds for working capital and general corporate purposes, including investor relations activities. The company paid E.F. Hutton & Co. a cash commission of $200,000, representing 4% of the gross proceeds, for serving as http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html Tue, 19 May 2026 07:00:27 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) completed a public offering that raised $5 million in gross proceeds through the sale of 2,659,574 common shares and common share equivalents at $1.88 per share.</p> <p>The pharmaceutical company issued 183,577 common shares and 2,475,997 pre-funded warrants to purchasers. Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.0001 per share.</p> <p>XORTX plans to use the net proceeds for working capital and general corporate purposes, including investor relations activities. The company paid E.F. Hutton & Co. a cash commission of $200,000, representing 4% of the gross proceeds, for serving as http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html Tue, 19 May 2026 07:00:27 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) completed a public offering that raised $5 million in gross proceeds through the sale of 2,659,574 common shares and common share equivalents at $1.88 per share.</p> <p>The pharmaceutical company issued 183,577 common shares and 2,475,997 pre-funded warrants to purchasers. Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.0001 per share.</p> <p>XORTX plans to use the net proceeds for working capital and general corporate purposes, including investor relations activities. The company paid E.F. Hutton & Co. a cash commission of $200,000, representing 4% of the gross proceeds, for serving as http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html Tue, 19 May 2026 07:00:27 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) completed a public offering that raised $5 million in gross proceeds through the sale of 2,659,574 common shares and common share equivalents at $1.88 per share.</p> <p>The pharmaceutical company issued 183,577 common shares and 2,475,997 pre-funded warrants to purchasers. Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.0001 per share.</p> <p>XORTX plans to use the net proceeds for working capital and general corporate purposes, including investor relations activities. The company paid E.F. Hutton & Co. a cash commission of $200,000, representing 4% of the gross proceeds, for serving as http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html Tue, 19 May 2026 07:00:27 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html <p>XORTX Therapeutics Inc. (NASDAQ: XRTX) completed a public offering that raised $5 million in gross proceeds through the sale of 2,659,574 common shares and common share equivalents at $1.88 per share.</p> <p>The pharmaceutical company issued 183,577 common shares and 2,475,997 pre-funded warrants to purchasers. Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.0001 per share.</p> <p>XORTX plans to use the net proceeds for working capital and general corporate purposes, including investor relations activities. The company paid E.F. Hutton & Co. a cash commission of $200,000, representing 4% of the gross proceeds, for serving as http://www.streetinsider.com/Equity+Offerings/XORTX+closes+%245+million+public+offering+of+shares+and+warrants/26517071.html Tue, 19 May 2026 07:00:27 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Press+Releases/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares (&quot;<strong>Common Shares</strong>&quot;) or common shares equivalents in lieu thereof (“<strong>Pre-Funded Warrants</strong>”) at a purchase price of US$1.88 (the “<strong>Offering</strong>”).</p> <p align="justify">In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Closing+of+US%245+Million+Public+Offering/26517035.html Tue, 19 May 2026 07:00:00 -0400 A.36078215 A.50215430 ANU O.02555813 O.28734418 O.34688637 XRTX XRTX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++XORTX+Therapeutics+Inc.+++For%3A+May+19/26517092.html si-local-file:///var/storage/secattach/20260519/26517092.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++XORTX+Therapeutics+Inc.+++For%3A+May+19/26517092.html Tue, 19 May 2026 07:00:00 -0400 O.28734418 XRTX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++XORTX+Therapeutics+Inc.+++For%3A+May+19/26517092.html si-local-file:///var/storage/secattach/20260519/26517092.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++XORTX+Therapeutics+Inc.+++For%3A+May+19/26517092.html Tue, 19 May 2026 07:00:00 -0400 O.28734418 XRTX